Literature DB >> 30465354

[Progress on medication-related osteonecrosis of the jaw].

Qi-Zhang Wang1, Ji-Yuan Liu1, Jian Pan1.   

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of bisphosphonates (BPs) or other targeted agent therapies. MRONJ appears as exposed bone, pus, and swelling in the oral and maxillofacial regions. However, neither surgery nor conservative therapy can eliminate symptoms thoroughly. In addition to BPs, several antiresorptive and antiangiogenic agents, such as denosumab and bevacizumab, as well as targeted agents, such as sunitinib and temsirolimus, can cause osteonecrosis of  the  jaw according to the literature. This review aims to summarize the research progress on these new drugs.

Entities:  

Keywords:  bevacizumab; bisphosphonates; denosumab; osteonecrosis

Mesh：

Substances：

Year:  2018        PMID： 30465354      PMCID： PMC7041135          DOI： 10.7518/hxkq.2018.05.019

Source DB:  PubMed          Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi        ISSN： 1000-1182


  39 in total

Review 1.  Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.

Authors:  Vittorio Fusco; Camillo Porta; Giorgia Saia; Chiara Paglino; Giordana Bettini; Matteo Scoletta; Riccardo Bonacina; Paolo Vescovi; Elisabetta Merigo; Giovanni Lo Re; Pamela Guglielmini; Olga Di Fede; Giuseppina Campisi; Alberto Bedogni
Journal:  Clin Genitourin Cancer       Date:  2014-12-09       Impact factor: 2.872

2.  Surgery Combined with LPRF in Denosumab Osteonecrosis of the Jaw: Case Report.

Authors:  Gustavo Maluf; Milena Correia de Pinho; Sandra Ribeiro de Barros da Cunha; Paulo Sérgio da Silva Santos; Eduardo Rodrigues Fregnani
Journal:  Braz Dent J       Date:  2016 May-Jun

3.  Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.

Authors:  Adepitan A Owosho; Ariel Blanchard; Lauren Levi; Arvin Kadempour; Haley Rosenberg; SaeHee K Yom; Azeez Farooki; Monica Fornier; Joseph M Huryn; Cherry L Estilo
Journal:  J Craniomaxillofac Surg       Date:  2015-12-20       Impact factor: 2.078

4.  Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling.

Authors:  Haiyong Wang; Chenyue Zhang; Zhouyu Ning; Litao Xu; Xiaoyan Zhu; Zhiqiang Meng
Journal:  Int J Oncol       Date:  2016-01-05       Impact factor: 5.650

5.  Osteonecrosis of the jaw a new complication related to Ipilimumab.

Authors:  Adepitan A Owosho; Michael Scordo; SaeHee K Yom; Joseph Randazzo; Paul B Chapman; Joseph M Huryn; Cherry L Estilo
Journal:  Oral Oncol       Date:  2015-10-05       Impact factor: 5.337

6.  Value of nonsurgical therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw.

Authors:  Jens Philipp Bodem; Steffen Kargus; Michael Engel; Jürgen Hoffmann; Christian Freudlsperger
Journal:  J Craniomaxillofac Surg       Date:  2015-06-03       Impact factor: 2.078

7.  Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw.

Authors:  K M Kim; W Park; S Y Oh; H-J Kim; W Nam; S-K Lim; Y Rhee; I H Cha
Journal:  Osteoporos Int       Date:  2014-02-20       Impact factor: 4.507

8.  Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.

Authors:  David Henry; Saroj Vadhan-Raj; Vera Hirsh; Roger von Moos; Vania Hungria; Luis Costa; Penella J Woll; Giorgio Scagliotti; Geoffrey Smith; Amy Feng; Susie Jun; Roger Dansey; Howard Yeh
Journal:  Support Care Cancer       Date:  2013-10-26       Impact factor: 3.603

9.  Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.

Authors:  J Bagan; A Peydró; J Calvo; M Leopoldo; Y Jiménez; L Bagan
Journal:  Oral Dis       Date:  2016-02-26       Impact factor: 3.511

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136
View more
  1 in total

1.  Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases.

Authors:  Victoria I Tofé; Leticia Bagán; José V Bagán
Journal:  J Clin Exp Dent       Date:  2020-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.